Cannara Historical Income Statement

LOVE Stock  CAD 0.75  0.05  6.25%   
Historical analysis of Cannara Biotech income statement accounts such as Selling General Administrative of 9.7 M can show how well Cannara Biotech performed in making a profits. Evaluating Cannara Biotech income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Cannara Biotech's future profits or losses.
 
Covid
Financial Statement Analysis is much more than just reviewing and examining Cannara Biotech latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Cannara Biotech is a good buy for the upcoming year.
  
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Cannara Biotech. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in income.

About Cannara Income Statement Analysis

Cannara Biotech Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Cannara Biotech shareholders. The income statement also shows Cannara investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).

Cannara Biotech Income Statement Chart

At this time, Cannara Biotech's Reconciled Depreciation is fairly stable compared to the past year. Income Before Tax is likely to climb to about 8.4 M in 2024, whereas Interest Income is likely to drop slightly above 181 K in 2024.

Interest Expense

The cost incurred by an entity for borrowed funds, including loans, bonds, or lines of credit.

Total Revenue

Total revenue comprises all receipts Cannara Biotech generated from the sale of its products or services. The total amount of income generated by the sale of goods or services related to the company's primary operations.

Operating Income

Operating Income is the amount of profit realized from Cannara Biotech operations after accounting for operating expenses such as cost of goods sold (COGS), wages and depreciation. Operating income takes the gross income and subtracts other operating expenses and then removes depreciation. Operating Income of Cannara Biotech is typically a synonym for earnings before interest and taxes (EBIT) and is also commonly referred to as operating profit or recurring profit. Earnings before interest and taxes (EBIT), representing the amount of profit a company generates from its operations.
Most accounts from Cannara Biotech's income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Cannara Biotech current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Cannara Biotech. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in income.
At this time, Cannara Biotech's Reconciled Depreciation is fairly stable compared to the past year. Income Before Tax is likely to climb to about 8.4 M in 2024, whereas Interest Income is likely to drop slightly above 181 K in 2024.
 2021 2022 2023 2024 (projected)
Gross Profit17.3M27.2M31.3M32.9M
Total Revenue35.8M57.3M65.8M69.1M

Cannara Biotech income statement Correlations

-0.29-0.86-0.98-0.98-0.84-0.71-0.79-0.8-0.97-0.98-0.96-0.71-0.73-0.830.97
-0.290.670.220.23-0.14-0.34-0.23-0.270.210.350.27-0.34-0.320.2-0.17
-0.860.670.790.80.490.30.440.440.780.870.860.30.320.79-0.81
-0.980.220.791.00.90.790.840.851.00.990.950.790.80.77-0.96
-0.980.230.81.00.90.780.840.851.00.990.960.780.80.78-0.96
-0.84-0.140.490.90.90.980.960.960.910.820.770.980.980.54-0.87
-0.71-0.340.30.790.780.980.960.960.80.680.631.01.00.42-0.77
-0.79-0.230.440.840.840.960.960.990.840.750.730.960.960.58-0.87
-0.8-0.270.440.850.850.960.960.990.850.760.760.960.960.63-0.88
-0.970.210.781.01.00.910.80.840.850.980.950.80.810.75-0.95
-0.980.350.870.990.990.820.680.750.760.980.980.680.690.81-0.94
-0.960.270.860.950.960.770.630.730.760.950.980.630.650.91-0.94
-0.71-0.340.30.790.780.981.00.960.960.80.680.631.00.42-0.77
-0.73-0.320.320.80.80.981.00.960.960.810.690.651.00.43-0.78
-0.830.20.790.770.780.540.420.580.630.750.810.910.420.43-0.83
0.97-0.17-0.81-0.96-0.96-0.87-0.77-0.87-0.88-0.95-0.94-0.94-0.77-0.78-0.83
Click cells to compare fundamentals

Cannara Biotech Account Relationship Matchups

Cannara Biotech income statement Accounts

201920202021202220232024 (projected)
Net Interest Income(1.1M)(1.7M)(3.2M)(5.0M)(4.5M)(4.3M)
Interest Income265.8K52.8K92.7K239.5K215.6K181.0K
Interest Expense1.3M1.6M1.9M3.9M4.5M4.7M
Selling General Administrative9.0M7.3M10.0M13.5M15.5M9.7M
Total Revenue2.5M16.3M35.8M57.3M65.8M69.1M
Gross Profit1.1M9.6M17.3M27.2M31.3M32.9M
Operating Income(11.9M)299.2K5.0M12.0M13.8M14.5M
Net Income From Continuing Ops(13.1M)(1.5M)2.3M6.9M8.0M8.4M
Ebit(9.9M)(12.0M)52.6K4.8M5.5M5.8M
Ebitda(10.9M)(9.2M)3.1M8.1M9.4M9.8M
Cost Of Revenue1.3M6.7M18.5M30.0M34.5M36.3M
Total Operating Expenses14.4M16.0M30.9M45.2M52.0M54.6M
Reconciled Depreciation2.6M3.0M3.9M4.9M5.7M6.0M
Income Before Tax(13.1M)(1.5M)2.3M6.9M8.0M8.4M
Net Income Applicable To Common Shares(12.3M)(12.5M)(1.5M)2.3M2.7M2.8M
Net Income(12.5M)(1.5M)2.3M6.9M8.0M8.4M
Total Other Income Expense Net(67.3K)(154.5K)551.4K(68.0K)(78.2K)(82.1K)

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for Cannara Stock Analysis

When running Cannara Biotech's price analysis, check to measure Cannara Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cannara Biotech is operating at the current time. Most of Cannara Biotech's value examination focuses on studying past and present price action to predict the probability of Cannara Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cannara Biotech's price. Additionally, you may evaluate how the addition of Cannara Biotech to your portfolios can decrease your overall portfolio volatility.